These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 10597730)

  • 21. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
    Aguilar LK; Guzik BW; Aguilar-Cordova E
    J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cryosurgery and immunotherapy for prostatic cancer.
    Loening S; Lubaroff D
    Urol Clin North Am; 1984 May; 11(2):327-36. PubMed ID: 6203207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunotherapy for colorectal cancer].
    Tougeron D; Fauquembergue É; Latouche JB
    Bull Cancer; 2013 Sep; 100(9):871-85. PubMed ID: 23917703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Considerations on clinical use of T cell immunotherapy for cancer.
    Plautz GE; Cohen PA; Shu S
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunotherapy of prostate cancer].
    Schulze H; Sommerfeld HJ
    Urologe A; 1993 Sep; 32(5):382-9. PubMed ID: 8212423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
    Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
    Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
    Lee Y; Bigner DD
    Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for melanoma.
    Komenaka I; Hoerig H; Kaufman HL
    Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.
    Slovin SF
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):972-80. PubMed ID: 18277959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current approaches in ovarian cancer vaccines.
    Reinartz S; Wagner U
    Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DC therapy for prostate cancer.
    Swindle PW; Tepes S; Clements J
    Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
    Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
    Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pitfalls or promise in prostate cancer immunotherapy-which is winning?
    Slovin SF
    Cancer J; 2008; 14(1):26-34. PubMed ID: 18303480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.